Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Perioperative blockage of beta-adrenoreceptors is widely used in cardiac and non-cardiac
surgery to reduce the rate of cardiovascular complications. Several randomized-controlled
studies and meta-analysis showed that esmolol reduces the incidence of myocardial ischemia
and arrhythmias in cardiac surgery as well as enhances postoperative cardiac performance. No
studies assessed the influence of esmolol in patients with hypertrophic obstructive
cardiomyopathy undergoing cardiac surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Meshalkin Research Institute of Pathology of Circulation